The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

The Microbiota Makes for Good Therapy The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors. The gut microbiota promote the efficacy of several antineoplastic agents in mice. Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of “pathogenic” T helper 17 (pTH17) cells and memory TH1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pTH17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pTH17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.

[1]  J. Qu,et al.  The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. , 2013, European journal of pharmacology.

[2]  S. Mazmanian,et al.  Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[3]  R. Ley,et al.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes , 2008, Nature.

[4]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[5]  E. Sugar,et al.  Reporting of preclinical tumor-graft cancer therapeutic studies , 2012, Cancer biology & therapy.

[6]  L. Bracci,et al.  Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. , 2011, Cancer research.

[7]  J. Doré,et al.  Biodiversity of the Mucosa‐Associated Microbiota Is Stable Along the Distal Digestive Tract in Healthy Individuals and Patients With Ibd , 2005, Inflammatory bowel diseases.

[8]  J. Doré,et al.  Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon , 2003, Gut.

[9]  C. Elson,et al.  A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota , 2009, Proceedings of the National Academy of Sciences.

[10]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[11]  N. McGovern,et al.  IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine Responses , 2013, Immunity.

[12]  S. Hapfelmeier,et al.  Intestinal bacterial colonization induces mutualistic regulatory T cell responses. , 2011, Immunity.

[13]  Georg Heinze,et al.  A comparative investigation of methods for logistic regression with separated or nearly separated data , 2006, Statistics in medicine.

[14]  T. Hudcovic,et al.  Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition , 2011, Clinical and experimental immunology.

[15]  Daniel G. Anderson,et al.  Origins of tumor-associated macrophages and neutrophils , 2012, Proceedings of the National Academy of Sciences.

[16]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[17]  B. Zhu,et al.  Comparative analysis of the distribution of segmented filamentous bacteria in humans, mice and chickens , 2012, The ISME Journal.

[18]  Todd Davidson,et al.  Generation of Pathogenic Th17 Cells in the Absence of TGF-β Signaling , 2010, Nature.

[19]  E. Böttger,et al.  Rapid determination of bacterial ribosomal RNA sequences by direct sequencing of enzymatically amplified DNA. , 1989, FEMS microbiology letters.

[20]  Christophe Benoist,et al.  Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. , 2010, Immunity.

[21]  A. Regev,et al.  Induction and molecular signature of pathogenic TH17 cells , 2012, Nature Immunology.

[22]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[23]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[24]  N. Kapel,et al.  Faecal D/L Lactate Ratio Is a Metabolic Signature of Microbiota Imbalance in Patients with Short Bowel Syndrome , 2013, PloS one.

[25]  L. Rice,et al.  Antimicrobial resistance in gram-positive bacteria. , 2006, The American journal of medicine.

[26]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[27]  L. Zitvogel,et al.  Cyclophosphamide induces differentiation of Th17 cells in cancer patients. , 2011, Cancer research.

[28]  E. Demidenko.  The assessment of tumour response to treatment , 2006 .

[29]  A. Haslberger,et al.  Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCR-DGGE Fingerprinting , 2011, PloS one.

[30]  James R. Cole,et al.  The Ribosomal Database Project: improved alignments and new tools for rRNA analysis , 2008, Nucleic Acids Res..

[31]  A. Macpherson,et al.  Interactions Between the Microbiota and the Immune System , 2012, Science.

[32]  R. Xavier,et al.  Angiotensin II drives the production of tumor-promoting macrophages. , 2013, Immunity.

[33]  H. Charles Romesburg,et al.  Exploring, Confirming, and Randomization Tests , 1985 .

[34]  W. Tissing,et al.  The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis , 2010, PLoS pathogens.

[35]  J. Doré,et al.  Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. , 2009, FEMS microbiology ecology.

[36]  L. Zitvogel,et al.  Immunomodulatory effects of cyclophosphamide and implementations for vaccine design , 2011, Seminars in Immunopathology.

[37]  P. Hugenholtz,et al.  Investigation of Candidate Division TM7, a Recently Recognized Major Lineage of the Domain Bacteria with No Known Pure-Culture Representatives , 2001, Applied and Environmental Microbiology.

[38]  R. Rudel,et al.  Estimating correlation with multiply censored data arising from the adjustment of singly censored data. , 2007, Environmental science & technology.

[39]  C. Hsieh,et al.  Peripheral education of the immune system by colonic commensal microbiota , 2011, Nature.

[40]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[41]  Adam Godzik,et al.  Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences , 2006, Bioinform..